FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1584179619> ?p ?o ?g. }

• W1584179619 endingPage "1644" @default.
• W1584179619 startingPage "1637" @default.
• W1584179619 abstract "BACKGROUND Omacetaxine, a protein synthesis inhibitor, is indicated in the United States for the treatment of patients with chronic‐phase (CP) or accelerated‐phase (AP) chronic myeloid leukemia (CML) with resistance and/or intolerance to 2 or more tyrosine kinase inhibitors. METHODS The final analysis, with 24 months of follow‐up, included additional efficacy and safety analyses to assess the benefit of long‐term omacetaxine administration (1.25 mg/m 2 twice daily for 14 days every 28 days followed by 7 days every 28 days) in CP‐CML and AP‐CML patients receiving >3 cycles. RESULTS Eighteen percent of CP‐CML patients achieved a major cytogenetic response (MCyR) with a median duration of 12.5 months (95% confidence interval [CI], 3.5 months to not reached [NR]); responses were maintained for ≥12 months in 3 of 14 responders, and the median overall survival (OS) was 40.3 months (95% CI, 23.8 months to NR). Among patients with AP‐CML, 14% achieved or maintained a major hematologic response for a median of 4.7 months (95% CI, 3.6 months to NR); MCyR was not achieved, and the median OS was 14.3 months (95% CI, 6.7‐18.7 months). In patients with CP‐CML and patients with AP‐CML who received >3 cycles of treatment (n = 50 and n = 14, respectively), the median OS was 49.3 months (95% CI, 23.8 months to NR) and 24.6 months (95% CI, 12‐37.2 months), respectively. Grade 3 or higher hematologic toxicities were the major side effects (79% and 73% for CP‐CML and AP‐CML, respectively), with discontinuation due to toxicity in 10% of CP patients and in 5% of AP patients. CONCLUSIONS These results suggest that the long‐term administration of omacetaxine is feasible with dose adjustments to manage toxicities and that omacetaxine provides a durable benefit for some patients. Cancer 2015;121:1637–1644 . © 2015 American Cancer Society ." @default.
• W1584179619 created "2016-06-24" @default.
• W1584179619 creator A5004249388 @default.
• W1584179619 creator A5014346242 @default.
• W1584179619 creator A5015140142 @default.
• W1584179619 creator A5037915760 @default.
• W1584179619 creator A5039028985 @default.
• W1584179619 creator A5042762794 @default.
• W1584179619 creator A5044224344 @default.
• W1584179619 creator A5051984074 @default.
• W1584179619 creator A5052875031 @default.
• W1584179619 creator A5055797334 @default.
• W1584179619 creator A5068339648 @default.
• W1584179619 creator A5068342352 @default.
• W1584179619 creator A5072027146 @default.
• W1584179619 creator A5074486986 @default.
• W1584179619 creator A5077014294 @default.
• W1584179619 creator A5078535679 @default.
• W1584179619 creator A5081397248 @default.
• W1584179619 creator A5089922903 @default.
• W1584179619 creator A5090435894 @default.
• W1584179619 date "2015-01-13" @default.
• W1584179619 modified "2023-10-16" @default.
• W1584179619 title "Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up" @default.
• W1584179619 cites W1975975368 @default.
• W1584179619 cites W1986058924 @default.
• W1584179619 cites W1991562382 @default.
• W1584179619 cites W2001678255 @default.
• W1584179619 cites W2012346470 @default.
• W1584179619 cites W2015616444 @default.
• W1584179619 cites W2016656445 @default.
• W1584179619 cites W2026327736 @default.
• W1584179619 cites W2031892240 @default.
• W1584179619 cites W2038119532 @default.
• W1584179619 cites W2047339299 @default.
• W1584179619 cites W2047725399 @default.
• W1584179619 cites W2057796192 @default.
• W1584179619 cites W2059441519 @default.
• W1584179619 cites W2074198797 @default.
• W1584179619 cites W2075193502 @default.
• W1584179619 cites W2083465317 @default.
• W1584179619 cites W2097799776 @default.
• W1584179619 cites W2101390452 @default.
• W1584179619 cites W2104694028 @default.
• W1584179619 cites W2107268345 @default.
• W1584179619 cites W2142711974 @default.
• W1584179619 cites W2142885433 @default.
• W1584179619 cites W2143939343 @default.
• W1584179619 cites W2156441544 @default.
• W1584179619 cites W2160848637 @default.
• W1584179619 cites W2165537263 @default.
• W1584179619 doi "https://doi.org/10.1002/cncr.29240" @default.
• W1584179619 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5650096" @default.
• W1584179619 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25586015" @default.
• W1584179619 hasPublicationYear "2015" @default.
• W1584179619 type Work @default.
• W1584179619 sameAs 1584179619 @default.
• W1584179619 citedByCount "42" @default.
• W1584179619 countsByYear W15841796192015 @default.
• W1584179619 countsByYear W15841796192016 @default.
• W1584179619 countsByYear W15841796192017 @default.
• W1584179619 countsByYear W15841796192018 @default.
• W1584179619 countsByYear W15841796192019 @default.
• W1584179619 countsByYear W15841796192020 @default.
• W1584179619 countsByYear W15841796192021 @default.
• W1584179619 countsByYear W15841796192022 @default.
• W1584179619 countsByYear W15841796192023 @default.
• W1584179619 crossrefType "journal-article" @default.
• W1584179619 hasAuthorship W1584179619A5004249388 @default.
• W1584179619 hasAuthorship W1584179619A5014346242 @default.
• W1584179619 hasAuthorship W1584179619A5015140142 @default.
• W1584179619 hasAuthorship W1584179619A5037915760 @default.
• W1584179619 hasAuthorship W1584179619A5039028985 @default.
• W1584179619 hasAuthorship W1584179619A5042762794 @default.
• W1584179619 hasAuthorship W1584179619A5044224344 @default.
• W1584179619 hasAuthorship W1584179619A5051984074 @default.
• W1584179619 hasAuthorship W1584179619A5052875031 @default.
• W1584179619 hasAuthorship W1584179619A5055797334 @default.
• W1584179619 hasAuthorship W1584179619A5068339648 @default.
• W1584179619 hasAuthorship W1584179619A5068342352 @default.
• W1584179619 hasAuthorship W1584179619A5072027146 @default.
• W1584179619 hasAuthorship W1584179619A5074486986 @default.
• W1584179619 hasAuthorship W1584179619A5077014294 @default.
• W1584179619 hasAuthorship W1584179619A5078535679 @default.
• W1584179619 hasAuthorship W1584179619A5081397248 @default.
• W1584179619 hasAuthorship W1584179619A5089922903 @default.
• W1584179619 hasAuthorship W1584179619A5090435894 @default.
• W1584179619 hasBestOaLocation W15841796191 @default.
• W1584179619 hasConcept C126322002 @default.
• W1584179619 hasConcept C141071460 @default.
• W1584179619 hasConcept C197934379 @default.
• W1584179619 hasConcept C2776694085 @default.
• W1584179619 hasConcept C2777063308 @default.
• W1584179619 hasConcept C2778729363 @default.
• W1584179619 hasConcept C44249647 @default.
• W1584179619 hasConcept C71924100 @default.
• W1584179619 hasConcept C90924648 @default.
• W1584179619 hasConceptScore W1584179619C126322002 @default.

• next